Provexis（PXS）株式概要Provexis plcは子会社とともに、機能性食品、医療用食品、栄養補助食品の開発、ライセンス供与、販売を世界中で行っている。 詳細PXS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間13.2%減少しました。 意味のある収益がありません ( £871K )UK市場と比較した過去 3 か月間の株価の変動+1 さらなるリスクすべてのリスクチェックを見るPXS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.011603.1% 割高 内在価値ディスカウントEst. Revenue$PastFuture-604k3m2016201920222025202620282031Revenue UK£2.7mEarnings UK£286.4kAdvancedSet Fair ValueView all narrativesProvexis plc 競合他社Potter & MooreSymbol: AIM:PAMMarket cap: UK£15.8mRevolution Beauty GroupSymbol: AIM:REVBMarket cap: UK£43.5mWarpaint LondonSymbol: AIM:W7LMarket cap: UK£169.7mVenture Life GroupSymbol: AIM:VLGMarket cap: UK£81.0m価格と性能株価の高値、安値、推移の概要Provexis過去の株価現在の株価UK£0.01152週高値UK£0.01552週安値UK£0.0055ベータ0.691ヶ月の変化2.27%3ヶ月変化4.65%1年変化73.08%3年間の変化114.29%5年間の変化12.50%IPOからの変化-82.21%最新ニュース分析記事 • May 25Is Provexis (LON:PXS) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£35.1m market cap, or US$47.9m).Reported Earnings • Jan 05First half 2026 earnings released: EPS: UK£0 (vs UK£0 in 1H 2025)First half 2026 results: EPS: UK£0 (in line with 1H 2025). Revenue: UK£364.4k (down 54% from 1H 2025). Net loss: UK£310.2k (loss widened 95% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.分析記事 • Dec 10We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.3m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.2m).Reported Earnings • Nov 02Full year 2025 earnings released: EPS: UK£0 (vs UK£0 in FY 2024)Full year 2025 results: EPS: UK£0 (in line with FY 2024). Revenue: UK£1.29m (up 61% from FY 2024). Net loss: UK£452.7k (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updates分析記事 • May 25Is Provexis (LON:PXS) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£35.1m market cap, or US$47.9m).Reported Earnings • Jan 05First half 2026 earnings released: EPS: UK£0 (vs UK£0 in 1H 2025)First half 2026 results: EPS: UK£0 (in line with 1H 2025). Revenue: UK£364.4k (down 54% from 1H 2025). Net loss: UK£310.2k (loss widened 95% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.分析記事 • Dec 10We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.3m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.2m).Reported Earnings • Nov 02Full year 2025 earnings released: EPS: UK£0 (vs UK£0 in FY 2024)Full year 2025 results: EPS: UK£0 (in line with FY 2024). Revenue: UK£1.29m (up 61% from FY 2024). Net loss: UK£452.7k (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Board Change • Oct 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomNew Risk • Jul 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£17.4m market cap, or US$23.3m).New Risk • May 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£13.4m market cap, or US$17.9m).Reported Earnings • Jan 03First half 2025 earnings released: EPS: UK£0 (vs UK£0 in 1H 2024)First half 2025 results: EPS: UK£0 (in line with 1H 2024). Revenue: UK£785.3k (up 103% from 1H 2024). Net loss: UK£159.1k (loss narrowed 40% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.New Risk • Dec 31New major risk - Revenue and earnings growthEarnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (UK£15.3m market cap, or US$19.1m).New Risk • Nov 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£191k free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£802k revenue, or US$1.0m). Market cap is less than US$100m (UK£15.9m market cap, or US$19.9m).Reported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United KingdomNew Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£13.6m market cap, or US$17.6m).New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£14.1m market cap, or US$17.8m).分析記事 • Mar 05We're Keeping An Eye On Provexis' (LON:PXS) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Dec 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£521k free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (UK£390k revenue, or US$490k). Minor Risk Market cap is less than US$100m (UK£14.9m market cap, or US$18.7m).Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.New Risk • Jul 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£12.8m market cap, or US$16.2m).分析記事 • Jan 21We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Sep 30Full year 2022 earnings released: EPS: UK£0 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0 (in line with FY 2021). Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jun 30We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Feb 15We're Not Worried About Provexis' (LON:PXS) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Oct 28We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • Oct 02Full year earnings released - UK£0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.株主還元PXSGB Personal ProductsGB 市場7D7.1%4.1%-0.9%1Y73.1%-9.8%18.7%株主還元を見る業界別リターン: PXS過去 1 年間で-9.8 % の収益を上げたUK Personal Products業界を上回りました。リターン対市場: PXS過去 1 年間で18.7 % の収益を上げたUK市場を上回りました。価格変動Is PXS's price volatile compared to industry and market?PXS volatilityPXS Average Weekly Movement10.7%Personal Products Industry Average Movement5.7%Market Average Movement5.5%10% most volatile stocks in GB Market10.9%10% least volatile stocks in GB Market3.0%安定した株価: PXSの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PXSの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUKの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19992Ian Fordwww.provexis.comProvexis plcは、その子会社とともに、世界中で機能性食品、医療用食品、栄養補助食品の開発、ライセンス供与、販売を行っている。同社は、様々な食品、飲料、栄養補助食品に使用される心臓発作や脳卒中などの心血管疾患に典型的に関連する異常な血液凝固の傾向を低減するトマト抽出物、Fruitflowのシロップと粉末バージョンを提供しています。また、栄養補助食品としてFruitflow+ Omega-3も提供している。同社はウェブサイトや代理店を通じて製品を販売している。Provexis plcは1999年に設立され、英国レディングに本社を置いている。もっと見るProvexis plc 基礎のまとめProvexis の収益と売上を時価総額と比較するとどうか。PXS 基礎統計学時価総額UK£29.32m収益（TTM）-UK£603.80k売上高(TTM)UK£871.27k30.3xP/Sレシオ-43.7xPER（株価収益率PXS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PXS 損益計算書（TTM）収益UK£871.27k売上原価UK£442.30k売上総利益UK£428.97kその他の費用UK£1.03m収益-UK£603.80k直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.00026グロス・マージン49.24%純利益率-69.30%有利子負債／自己資本比率0%PXS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 18:38終値2026/06/25 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Provexis plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
分析記事 • May 25Is Provexis (LON:PXS) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£35.1m market cap, or US$47.9m).
Reported Earnings • Jan 05First half 2026 earnings released: EPS: UK£0 (vs UK£0 in 1H 2025)First half 2026 results: EPS: UK£0 (in line with 1H 2025). Revenue: UK£364.4k (down 54% from 1H 2025). Net loss: UK£310.2k (loss widened 95% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
分析記事 • Dec 10We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.3m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.2m).
Reported Earnings • Nov 02Full year 2025 earnings released: EPS: UK£0 (vs UK£0 in FY 2024)Full year 2025 results: EPS: UK£0 (in line with FY 2024). Revenue: UK£1.29m (up 61% from FY 2024). Net loss: UK£452.7k (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
分析記事 • May 25Is Provexis (LON:PXS) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£546k free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£871k revenue, or US$1.2m). Market cap is less than US$100m (UK£35.1m market cap, or US$47.9m).
Reported Earnings • Jan 05First half 2026 earnings released: EPS: UK£0 (vs UK£0 in 1H 2025)First half 2026 results: EPS: UK£0 (in line with 1H 2025). Revenue: UK£364.4k (down 54% from 1H 2025). Net loss: UK£310.2k (loss widened 95% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
分析記事 • Dec 10We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.3m revenue, or US$1.7m). Market cap is less than US$100m (UK£13.7m market cap, or US$18.2m).
Reported Earnings • Nov 02Full year 2025 earnings released: EPS: UK£0 (vs UK£0 in FY 2024)Full year 2025 results: EPS: UK£0 (in line with FY 2024). Revenue: UK£1.29m (up 61% from FY 2024). Net loss: UK£452.7k (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Board Change • Oct 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Oct 30Provexis plc to Report Q2, 2026 Results on Oct 30, 2025Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025
お知らせ • Sep 30Provexis plc, Annual General Meeting, Nov 21, 2025Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
New Risk • Jul 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£17.4m market cap, or US$23.3m).
New Risk • May 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£13.4m market cap, or US$17.9m).
Reported Earnings • Jan 03First half 2025 earnings released: EPS: UK£0 (vs UK£0 in 1H 2024)First half 2025 results: EPS: UK£0 (in line with 1H 2024). Revenue: UK£785.3k (up 103% from 1H 2024). Net loss: UK£159.1k (loss narrowed 40% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
New Risk • Dec 31New major risk - Revenue and earnings growthEarnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (UK£15.3m market cap, or US$19.1m).
New Risk • Nov 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£191k free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Revenue is less than US$5m (UK£802k revenue, or US$1.0m). Market cap is less than US$100m (UK£15.9m market cap, or US$19.9m).
Reported Earnings • Oct 01Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023)Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 01Provexis plc, Annual General Meeting, Oct 25, 2024Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom
New Risk • Jul 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£13.6m market cap, or US$17.6m).
New Risk • Mar 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Share price has been volatile over the past 3 months (9.9% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (UK£14.1m market cap, or US$17.8m).
分析記事 • Mar 05We're Keeping An Eye On Provexis' (LON:PXS) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Dec 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£521k free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (UK£390k revenue, or US$490k). Minor Risk Market cap is less than US$100m (UK£14.9m market cap, or US$18.7m).
Reported Earnings • Oct 01Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022)Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Sep 30Provexis plc, Annual General Meeting, Oct 26, 2023Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters.
New Risk • Jul 03New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£12.8m market cap, or US$16.2m).
分析記事 • Jan 21We're Not Very Worried About Provexis' (LON:PXS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Dec 31First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022)First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 30Full year 2022 earnings released: EPS: UK£0 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0 (in line with FY 2021). Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jun 30We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Feb 15We're Not Worried About Provexis' (LON:PXS) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Oct 28We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To GrowThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • Oct 02Full year earnings released - UK£0.0002 loss per shareOver the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year.
